Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Net Assets
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has net assets worth CN¥9.15 Billion CNY (≈ $1.34 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.87 Billion ≈ $1.44 Billion USD) and total liabilities (CN¥719.98 Million ≈ $105.36 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002773 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.15 Billion |
| % of Total Assets | 92.71% |
| Annual Growth Rate | 20.31% |
| 5-Year Change | 50.23% |
| 10-Year Change | 242.45% |
| Growth Volatility | 13.62 |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Chengdu Kanghong Pharmaceuticals Group C asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2024)
The table below shows the annual net assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2024. For live valuation and market cap data, see Chengdu Kanghong Pharmaceuticals Group C market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.65 Billion ≈ $1.27 Billion |
+10.69% |
| 2023-12-31 | CN¥7.81 Billion ≈ $1.14 Billion |
+13.10% |
| 2022-12-31 | CN¥6.91 Billion ≈ $1.01 Billion |
+13.13% |
| 2021-12-31 | CN¥6.10 Billion ≈ $893.35 Million |
+6.07% |
| 2020-12-31 | CN¥5.76 Billion ≈ $842.26 Million |
+24.57% |
| 2019-12-31 | CN¥4.62 Billion ≈ $676.13 Million |
+13.14% |
| 2018-12-31 | CN¥4.08 Billion ≈ $597.61 Million |
+15.25% |
| 2017-12-31 | CN¥3.54 Billion ≈ $518.52 Million |
+21.98% |
| 2016-12-31 | CN¥2.90 Billion ≈ $425.08 Million |
+15.04% |
| 2015-12-31 | CN¥2.52 Billion ≈ $369.49 Million |
+56.66% |
| 2014-12-31 | CN¥1.61 Billion ≈ $235.85 Million |
+16.01% |
| 2013-12-31 | CN¥1.39 Billion ≈ $203.30 Million |
+25.60% |
| 2012-12-31 | CN¥1.11 Billion ≈ $161.87 Million |
+18.13% |
| 2011-12-31 | CN¥936.39 Million ≈ $137.02 Million |
+49.86% |
| 2010-12-31 | CN¥624.85 Million ≈ $91.44 Million |
+15.77% |
| 2009-12-31 | CN¥539.75 Million ≈ $78.98 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Kanghong Pharmaceuticals Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1787.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.22 Billion | 60.36% |
| Common Stock | CN¥919.78 Million | 10.63% |
| Other Components | CN¥2.51 Billion | 29.01% |
| Total Equity | CN¥8.65 Billion | 100.00% |
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Market Cap
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amedisys Inc
NASDAQ:AMED
|
$3.32 Billion |
|
Autel Intelligent Technology Corp Ltd
SHG:688208
|
$3.32 Billion |
|
China Petroleum Engineering Corp
SHG:600339
|
$3.33 Billion |
|
Huber+suhner AG
SW:HUBN
|
$3.33 Billion |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
$3.32 Billion |
|
Trigano S.A.
PA:TRI
|
$3.32 Billion |
|
CI Financial Corp
TO:CIX
|
$3.32 Billion |
|
WesBanco Inc
NASDAQ:WSBC
|
$3.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Kanghong Pharmaceuticals Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,804,029,406 to 8,653,202,130, a change of 849,172,724 (10.9%).
- Net income of 1,191,230,761 contributed positively to equity growth.
- Dividend payments of 349,396,302 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.19 Billion | +13.77% |
| Dividends Paid | CN¥349.40 Million | -4.04% |
| Other Changes | CN¥7.34 Million | +0.08% |
| Total Change | CN¥- | 10.88% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Kanghong Pharmaceuticals Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.61x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.35x to 2.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.84 | CN¥24.63 | x |
| 2010-12-31 | CN¥0.96 | CN¥24.63 | x |
| 2011-12-31 | CN¥1.24 | CN¥24.63 | x |
| 2012-12-31 | CN¥1.40 | CN¥24.63 | x |
| 2013-12-31 | CN¥1.76 | CN¥24.63 | x |
| 2014-12-31 | CN¥2.04 | CN¥24.63 | x |
| 2015-12-31 | CN¥3.03 | CN¥24.63 | x |
| 2016-12-31 | CN¥3.33 | CN¥24.63 | x |
| 2017-12-31 | CN¥4.02 | CN¥24.63 | x |
| 2018-12-31 | CN¥4.70 | CN¥24.63 | x |
| 2019-12-31 | CN¥5.29 | CN¥24.63 | x |
| 2020-12-31 | CN¥6.26 | CN¥24.63 | x |
| 2021-12-31 | CN¥6.62 | CN¥24.63 | x |
| 2022-12-31 | CN¥7.51 | CN¥24.63 | x |
| 2023-12-31 | CN¥8.52 | CN¥24.63 | x |
| 2024-12-31 | CN¥9.44 | CN¥24.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Kanghong Pharmaceuticals Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.77%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.75%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.08x
- Recent ROE (13.77%) is below the historical average (14.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 15.27% | 12.92% | 0.78x | 1.53x | CN¥28.47 Million |
| 2010 | 17.59% | 13.63% | 0.80x | 1.61x | CN¥46.82 Million |
| 2011 | 17.83% | 16.23% | 0.78x | 1.40x | CN¥72.45 Million |
| 2012 | 18.56% | 15.23% | 0.90x | 1.36x | CN¥93.49 Million |
| 2013 | 23.01% | 21.38% | 0.87x | 1.24x | CN¥178.49 Million |
| 2014 | 17.18% | 16.33% | 0.86x | 1.22x | CN¥114.31 Million |
| 2015 | 15.74% | 18.98% | 0.72x | 1.16x | CN¥143.64 Million |
| 2016 | 17.10% | 19.56% | 0.68x | 1.29x | CN¥206.26 Million |
| 2017 | 18.18% | 23.12% | 0.61x | 1.29x | CN¥289.85 Million |
| 2018 | 17.02% | 23.82% | 0.56x | 1.27x | CN¥286.55 Million |
| 2019 | 15.54% | 22.05% | 0.56x | 1.26x | CN¥256.14 Million |
| 2020 | -4.69% | -8.19% | 0.47x | 1.22x | CN¥-845.43 Million |
| 2021 | 6.91% | 11.68% | 0.52x | 1.14x | CN¥-187.89 Million |
| 2022 | 12.99% | 26.46% | 0.44x | 1.12x | CN¥206.49 Million |
| 2023 | 13.39% | 26.40% | 0.46x | 1.09x | CN¥264.36 Million |
| 2024 | 13.77% | 26.75% | 0.48x | 1.08x | CN¥325.91 Million |
Industry Comparison
This section compares Chengdu Kanghong Pharmaceuticals Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) | CN¥9.15 Billion | 15.27% | 0.08x | $3.32 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.